 | | Vol. 12.43 – 2 November, 2021 |
| |
|
|
| Investigators showed that concurrent ASXL1 and NRAS mutations defined a population of chronic myelomonocytic leukemia patients with shorter leukemia-free survival than those with ASXL1 mutation only.
[Blood] |
|
 |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors analyzed exome sequencing data from the UK Biobank, and found clonal hematopoiesis of indeterminate potential to be associated with increased incident osteoporosis diagnoses and decreased bone mineral density.
[Journal of Experimental Medicine] |
|
|
|
| Scientists showed that DNMT3A mutations underlied a defect in recovery from replication fork arrest with subsequent accumulation of unresolved DNA damage, which might have therapeutic tractability.
[Clinical Cancer Research] |
|
|
|
| Researchers used cellular, mouse, and humanized models of RAC-dependent BCR-ABL1-driven and Ph-like acute lymphoblastic leukemia to identify VAV3, a tyrosine phosphorylation–dependent RAC guanine nucleotide exchange factor (RacGEF), as the target of the small molecule IODVA1.
[Leukemia] |
|
|
|
| Investigators examined the effect of increased TGFβ signaling in combination or not with an acute innate immune challenge and used polyinosinc:polycytidilic acid on the hematopoietic system without genetic mutations.
[Haematologica] |
|
|
|
| While hematopoietic-specific Cited2 deletion had a minor impact on steady-state hematopoiesis, Cited2-deficient hematopoietic stem cells were severely depleted in young mice and failed to expand upon aging.
[Stem Cell Reports] |
|
|
|
| The authors proposed the MBU-7 and MBU-8 cell lines as suitable in vitro models for screening and testing vulnerabilities that were associated with the disease-relevant polysomies of chromosome 7, 8 and 18.
[Scientific Reports] |
|
|
|
| Scientists used peripheral blood and bone marrow samples from patients with acute myeloid leukemia (AML) and analyzed the impact of CD157-directed antibodies in AML survival and in response to cytarabine ex vivo.
[Scientific Reports] |
| |
|
|
| Researchers performed a meta-analysis of three genome-wide association studies, with replication in a fourth study, and incorporated a total of 4018 acute myeloid leukemia (AML) cases and 10488 controls, and identified a genome-wide significant risk locus for AML at 11q13.2.
[Nature Communications] |
|
|
|
| Investigators explored 51 variants within 17 DNA-repair genes for their association with acute graft versus host disease grades 2–4 in 60 pediatric patients.
[Pharmacogenomics Journal] |
|
|
|
| The authors investigated the incidence of, and risk factors for, asparaginase-associated pancreatitis in pediatric patients with acute lymphoblastic leukemia (ALL) and found that the incidence of acute pancreatitis in childhood ALL was correlated more strongly with the peak dose intensity than with the cumulative dose of L-Asparaginase.
[Pediatric Research] |
|  |
|
|
|
| Scientists summarize the results of single-cell sequencing of peripheral blood, lung tissue, and cerebrospinal fluid of COVID-19 patients and describe the differentiation trajectory of myeloid cells in patients.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Investigators address treatment duration and sequence considerations and discuss current targeted treatment dilemmas of chronic lymphocytic leukemia, where they review B cell lymphoma 2 inhibitors and Bruton’s tyrosine kinase in a fixed duration and continuous treatment manner.
[Hematological Oncology] |
|
|
|
|
| Precigen, Inc. announced that the US FDA has cleared the Investigational New Drug application to initiate the Phase I/Ib clinical trial of PRGN-3007 in advanced receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) hematological and solid tumors.
[Precigen, Inc.] |
|
|
|
| Novartis, Inc. announced today that the US FDA approved Scemblix® for the treatment of chronic myeloid leukemia in two distinct indications.
[Novartis, Inc.] |
|
|
|
|
| December 8 – 9, 2021
Virtual |
|
|
|
|
|
| | University Children’s Hospital Zurich – Zurich, Switzerland |
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| | Boston Children’s Hospital – Boston, Massachusetts, United States |
|
|
|
| | University of Manitoba – Winnipeg, Manitoba, Canada |
|
|
|
| | The University of Kansas – Kansas City, Kansas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
